Compare National Beverage Corp. (FIZZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Merck & Co., Inc. — how do they compare? National Beverage Corp. trades at $30.57 (market cap $2.89B), while Merck & Co., Inc. trades at $133.51 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 111.3× National Beverage Corp.'s market cap, and Merck & Co., Inc. pays a 2.61% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | MRK | |
|---|---|---|
Market Cap | $2.89B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $131.84 |
52-Week Low | $30.53 | $77.60 |
Enterprise Value | $2.60B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.45, down 1.9% on the day, with a bearish technical signal and recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margin improved to 15.56% in 2025. The company announced a special dividend of $3.25 per share, payable in July 2026, but faces declining LaCroix volumes and muted growth prospects.
The outlook is cautious due to stalled growth and bearish analyst sentiment, with 50% of coverage rating Sell. Risks include competitive pressures and weak volume trends, though the dividend provides some shareholder return. Upside appears limited without a clear catalyst for revenue acceleration.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
